Article: Nicotinamide Riboside Prevents SARM1-Induced NAD+ and ATP Depletion: Preclinical Findings

PrevNext
Neurological Health Parkinson's Disease Preclinical

Nicotinamide Riboside Prevents SARM1-Induced NAD+ and ATP Depletion: Preclinical Findings

Synopsis

Mitochondrial dysfunction is a key feature of neurodegenerative diseases like Parkinson’s. SARM1 promotes nerve damage by breaking down NAD+, and its activity is increased when phosphorylated at serine 548 by JNK under oxidative stress. This leads to reduced mitochondrial function and ATP levels, making neurons more vulnerable. Notably, supplementation with the NAD+ precursor nicotinamide riboside (NR) suppressed SARM1-induced NAD+ and ATP loss in a dose-dependent manner. These results suggest that abnormal SARM1 activation contributes to neuronal energy failure, and boosting NAD+ with NR may help protect neurons in Parkinson’s and other neurodegenerative diseases.

Journal

Journal of Biological Chemistry

Share

Read more

Preclinical

Nicotinamide and Nicotinamide Riboside Induce Rapid Differentiation and Function in Retinal Pigment Epithelial Cells: Preclinical Findings

Synopsis Human retinal pigment epithelial (RPE) cells, especially the ARPE-19 cell line, are commonly used in eye and general epithelial cell research. While they are convenient and consistent, th...

Read more
Alzheimer's Disease

The Effects of NAD+ Boosting in Mitochondrial DNA Depletion Syndrome: Preclinical Findings

Synopsis Patients with mtDNA depletion syndrome 3 (MTDPS3) often die young from liver failure due to severely reduced mitochondrial DNA. Research into treatments has been difficult because MTDPS3 ...

Read more